Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study.

Anton Hagenbeek,Hans Mooij,Josée Zijlstra,Pieternella Lugtenburg,Gustaaf van Imhoff,Marcel Nijland,Sanne Tonino,Martin Hutchings,Marjolein Spiering,Roberto Liu,Harm van Tinteren,Marie José Kersten

HAEMATOLOGICA（2019）

引用 19|浏览29

暂无评分

摘要

Clinical activity of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, has been demonstrated in relapsed/refractory classical Hodgkin Lymphoma (R/R cHL) in pivotal phase I and phase II studies.[1][1],[2][2] Adverse events ascribed to BV as single agent are mostly mild and reversible.[3

查看译文

关键词

Conditioning Regimen,Hodgkin's Lymphoma,Molecular Pharmacology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要